#ASC020 - Twitter Hashtag

over 3 years ago

Dominant Space & Jennifer Sumire — Spread Your Wings (Codeswitch Remix) Trance Ascent Recordings #ASC020 07.04.2023 https://t.co/2wcNWcnneP https://t.co/BPv6pS8KTq Angels unite! A soaring new cover of "Spread Your Wings" by System F and Morgan Jalsing is b https://t.co/egoTu26PLr

Trance__ONE's tweet photo. Dominant Space & Jennifer Sumire — Spread Your Wings (Codeswitch Remix)
Trance
Ascent Recordings #ASC020
07.04.2023
https://t.co/2wcNWcnneP
https://t.co/BPv6pS8KTq
Angels unite! A soaring new cover of "Spread Your Wings" by System F and Morgan Jalsing is b
https://t.co/egoTu26PLr https://t.co/h40mGjU0Th

0

2

0

344

CancerDotNet @CancerDotNet

over 6 years ago

🎧 Listen 🔔 New #cancerresearch for treatment of #leukemia #colorectalcancer and #lungcancer - @LurieCancer’s @jaltmanmd and @JPatelMD, and @DanaFarber's Dr. Jeffrey Meyerhardt share exciting developments - #ASC020 #ResearchRoundup Vol. 1 Available Now! https://t.co/Ws8RviSPWy

0

5

1

0

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

over 6 years ago

Keep the responses coming! OS seems to be important, we all agree, but do we treat today based on available DFS? #ASC020

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

over 6 years ago

Yesterday, we saw impressive DFS HR of 0.17 for adjuvant osimertinib in pts with Stage II-IIIA, and 0.21 including IB #NSCLC #ADAURA It's now post #ASCO20 Monday Morning, would you prescribe osi for: @JackWestMD @n8pennell @StephenVLiu @LeciaSequist @Jbauml @HosseinBorghaei

0

11

3

5

0

2

6

0

Miral Amin, MD, FACS, MBA (She/her) @therealmiral

over 6 years ago

#ASC020 : PPI added to chemo improved response rates #bcsm @ASBrS

MDedge Hematology & Oncology @MDedgeHemOnc

over 6 years ago

#ASCO20: PPI + chemo improves breast tumor response rates in phase 2 trial. https://t.co/0mhdMdagjT #ASCO2020 @ASCO #Oncoalert #cancer

MDedgeHemOnc's tweet photo. #ASCO20: PPI + chemo improves breast tumor response rates in phase 2 trial. https://t.co/0mhdMdagjT #ASCO2020 @ASCO #Oncoalert #cancer https://t.co/laciyFyVlS

0

5

2

0

1

0

Neelima Denduluri @ndenduluri1

over 6 years ago

Thanks @dave6408 for explaining adjuvant therapy in a way we can all understand - I wil definitely incorporate that slide next time I give a lecture on #adjuvant therapy! Excellent presentation #ASC020 #MedEd @SarahCannonDocs @ASCOPres @MLJohnsonMD2

Stephen V Liu, MD

@StephenVLiu

over 6 years ago

#ASCO20 Discussion of #ADAURA provided by @dave6408 of @SarahCannonDocs reminding us why we give adjuvant therapy after surgery for NSCLC. Are we curing or are we controlling/delaying? We view toxicity (physical and financial) differently in these two situations. #OncoAlert

StephenVLiu's tweet photo. #ASCO20 Discussion of #ADAURA provided by @dave6408 of @SarahCannonDocs reminding us why we give adjuvant therapy after surgery for NSCLC. Are we curing or are we controlling/delaying? We view toxicity (physical and financial) differently in these two situations. #OncoAlert https://t.co/tSPvznDLir

1

24

9

3

0

1

11

0

1

0

George W Sledge MD @GeorgeSledge51

over 6 years ago

HERCLIMB results: CNS-PFS benefits confirmed and OS benefits now seen with 1 year landmark analysis showing 70.1% vs 46.7% and median OS of 18.1 vs 12 months. Seen in active brain mets as well. Higher CNS RR as well. Great data. Real. #ASC020 #bcsm

0

31

6

1

0

George W Sledge MD @GeorgeSledge51

over 6 years ago

PHOEBE results: pyrotinib PFS significantly > lapatinib (12.5 vs 6.8 mo, p< .001, HR 0.39. OS immature but trending for pyrotinib. More diarrhea with pyrotinib. My thoughts: good data, and pyr better than lap, but very different pts. No T-DM1 or pertuzumab. #ASC020 #bcsm

0

6

1

0

George W Sledge MD @GeorgeSledge51

over 6 years ago

PHOEBE trial from China randomized pts to Cape + lapatinib vs Cape + the pan-ErbB RTKi pyrotinib. All had prior trastuzumab and taxanes and/or anthracyclines & up to 2 prior CT for MBC. Primary endpoint was PFS, N = 267, and 1/4 were resistant to prior trastuzumab. #ASC020 #bcsm

0

9

1

0

George W Sledge MD @GeorgeSledge51

over 6 years ago

TBCRC 048 cont: pts got olaparib 300mg bid q3w until PD. 27 germline non BRCA and 26 somatic. 87% had mutations in ATM, CHEK2, PALB2 or sBRCA1/2. Cohort 1: 33% PR, all in PALB2 (9/11). Cohort 2: 31% PR. Nice data, and supports prior Talazoparib results. #ASC020 #bcsm

0

8

0

1

0

George W Sledge MD @GeorgeSledge51

over 6 years ago

TBCRC 048 Phase 2 study of olaparib in MBC with germline or somatic mutations in DNA damage repair genes, presented by Dr. Nadine Tung. Primary endpoint is ORR in Stage 4 with no more than 2 CT regimens in the metastatic setting. Not platinum refractory. #ASC020 #bcsm

0

7

0

George W Sledge MD @GeorgeSledge51

over 6 years ago

I need a break. Been thinking about Virtual ASCO20. Pro: the meeting is still on, having slides next to video allows deeper data dive and I can eat dinner between talks. Con: I miss my friends, the video works only half the time and it feels like homework. Thoughts? #ASC020 #bcsm

30

295

20

3

0

Wungki Park, MD MS

@CentralParkWMD

over 6 years ago

Trial in progress. A novel siRNA targeting #KRAS in locally advanced #PancreaticCancer A phase II study of siG12D-LODER in combination with chemotherapy in LAPC (PROTACT) #PancSM @AnnaVarghese4 @EileenMOReilly #ASC020 https://t.co/2S2FgnigPR

CentralParkWMD's tweet photo. Trial in progress. A novel siRNA targeting #KRAS in locally advanced #PancreaticCancer A phase II study of siG12D-LODER in combination with chemotherapy in LAPC (PROTACT) #PancSM @AnnaVarghese4 @EileenMOReilly #ASC020 https://t.co/2S2FgnigPR https://t.co/OeL1y9lTX6

0

17

6

4

0

Herbert Irving Comprehensive Cancer Center @columbiacancer

over 6 years ago

Don't miss Dr. @SLentzsch discuss plasma cell dyscrasia at tomorrow's Hematologic Malignancies: Highlights of the Day session! Broadcasting LIVE at 11:30AM! #ASC020 #mmsm https://t.co/aVdHAcwjTR